Progress and opportunities for immune therapeutics in osteosarcoma

Christina K. Lettieri, Nicole Appel, Nicole Labban, Danielle M. Lussier, Joseph Blattman, Pooja Hingorani

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.

Original languageEnglish (US)
Pages (from-to)1233-1244
Number of pages12
JournalImmunotherapy
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Osteosarcoma
Therapeutics
Neoplasms
Cancer Vaccines
Immunotherapy
Monoclonal Antibodies
Antigens
Survival
Pharmaceutical Preparations

Keywords

  • clinical trials
  • immune checkpoint inhibitors
  • immune tolerance
  • immunotherapy
  • osteosarcoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Lettieri, C. K., Appel, N., Labban, N., Lussier, D. M., Blattman, J., & Hingorani, P. (2016). Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy, 8(10), 1233-1244. https://doi.org/10.2217/imt-2016-0048

Progress and opportunities for immune therapeutics in osteosarcoma. / Lettieri, Christina K.; Appel, Nicole; Labban, Nicole; Lussier, Danielle M.; Blattman, Joseph; Hingorani, Pooja.

In: Immunotherapy, Vol. 8, No. 10, 01.10.2016, p. 1233-1244.

Research output: Contribution to journalReview article

Lettieri, CK, Appel, N, Labban, N, Lussier, DM, Blattman, J & Hingorani, P 2016, 'Progress and opportunities for immune therapeutics in osteosarcoma', Immunotherapy, vol. 8, no. 10, pp. 1233-1244. https://doi.org/10.2217/imt-2016-0048
Lettieri CK, Appel N, Labban N, Lussier DM, Blattman J, Hingorani P. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy. 2016 Oct 1;8(10):1233-1244. https://doi.org/10.2217/imt-2016-0048
Lettieri, Christina K. ; Appel, Nicole ; Labban, Nicole ; Lussier, Danielle M. ; Blattman, Joseph ; Hingorani, Pooja. / Progress and opportunities for immune therapeutics in osteosarcoma. In: Immunotherapy. 2016 ; Vol. 8, No. 10. pp. 1233-1244.
@article{e6404861d5fd427aa2b1045b950da227,
title = "Progress and opportunities for immune therapeutics in osteosarcoma",
abstract = "Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.",
keywords = "clinical trials, immune checkpoint inhibitors, immune tolerance, immunotherapy, osteosarcoma",
author = "Lettieri, {Christina K.} and Nicole Appel and Nicole Labban and Lussier, {Danielle M.} and Joseph Blattman and Pooja Hingorani",
year = "2016",
month = "10",
day = "1",
doi = "10.2217/imt-2016-0048",
language = "English (US)",
volume = "8",
pages = "1233--1244",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Progress and opportunities for immune therapeutics in osteosarcoma

AU - Lettieri, Christina K.

AU - Appel, Nicole

AU - Labban, Nicole

AU - Lussier, Danielle M.

AU - Blattman, Joseph

AU - Hingorani, Pooja

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.

AB - Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.

KW - clinical trials

KW - immune checkpoint inhibitors

KW - immune tolerance

KW - immunotherapy

KW - osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84986877550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986877550&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0048

DO - 10.2217/imt-2016-0048

M3 - Review article

VL - 8

SP - 1233

EP - 1244

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 10

ER -